Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Hematology
•
General Rheumatology
•
Dermatology
•
Pediatric Rheumatology
What is your approach to treatment in patients with cutaneous mastocytosis and inflammatory arthritis?
Related Questions
What is your approach to evaluation in patients who present with erythromelalgia?
What is your approach to DVT prophylaxis in patients who require IVIG but are at increased risk for thrombotic events?
Would you start anticoagulation in a previously heathy patient with a new diagnosis of ANCA vasculitis (+PR3, RPGN, crescents on kidney biopsy) who presented with pancreatitis, splenic and renal infarcts and was also found to have CMV viremia?
How do you approach evaluation for underlying rheumatologic disease in patients with chronic asymptomatic thrombocytopenia?
How would approach the management of a patient with significantly positive anticardiolopin and beta 2 glycoprotein antibodies in the absence of any clotting (including obstetric) history but with significant thrombocytopenia (but no other features of active connective tissue disease)?
What is your approach to using topical JAK inhibitors in the management of cutaneous manifestations of rheumatic disease?
How do you counsel and manage joint pain after isotretinoin treatment?
How do you approach evaluation and management of arthralgia in a patient after CAR-T cell therapy?
Have you seen drug induced SCLE from IL-17 inhibitors?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
